Focusing on intestinal tumours, we assessed the prognostic value of GNL and further compared it with other clinically relevant gastric cancer biomarkers, including E-cadherin, p53, MSI, and the cancer-associated glycans sTn and sLeA. Here, CDH1 is linked to intestinal neoplasm.